U.S. markets close in 42 minutes

GlaxoSmithKline plc (GSK)

NYSE - Nasdaq Real Time Price. Currency in USD
Add to watchlist
35.23-0.06 (-0.18%)
As of 3:18PM EDT. Market open.
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
Short-term KST

Short-term KST

Previous Close35.29
Open35.43
Bid35.25 x 900
Ask35.24 x 900
Day's Range34.99 - 35.46
52 Week Range31.43 - 48.25
Volume2,851,002
Avg. Volume3,313,510
Market Cap88.008B
Beta (5Y Monthly)0.34
PE Ratio (TTM)35.51
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & Yield1.89 (5.35%)
Ex-Dividend DateMay 14, 2020
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued
-27% Est. Return
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
  • Is a Beat in Store for Glaxo (GSK) This Earnings Season?
    Zacks

    Is a Beat in Store for Glaxo (GSK) This Earnings Season?

    Glaxo's (GSK) Pharmaceutical and Consumer Healthcare segments are likely to have driven third-quarter sales. Results will provide clarity on the impact of coronavirus on the company's vaccine business.

  • As COVID-19 cases spike, pneumonia vaccine demand rockets and Europe runs low
    Reuters

    As COVID-19 cases spike, pneumonia vaccine demand rockets and Europe runs low

    As COVID-19 infections rise, people seeking to avoid one lung disease compounding another are queuing up to get inoculated against bacterial pneumonia, causing shortages of a Merck & Co vaccine in parts of Europe. Demand for Merck's Pneumovax 23, which is used to prevent pneumococcal lung infections, has hit record highs across the world, the company said. Pneumococcal prevention, the largest segment of the vaccine market by value, rang up about $7 billion in sales in 2019, contested by Pfizer, Merck and GlaxoSmithKline.

  • Barrons.com

    Glaxo Vaccines Target Another Viral Threat

    GlaxoSmithKline is testing two vaccines that could protect newborns and people over age 60 from RSV, a virus that has defied vaccine developers for years.